Released Nov 10, 2026, before the open
10-Q filed Nov 10, 2026, 41 days after period end · 0001104659-26-124771
What the release said
Net income for the three months ended September 30, 2026 was $4.0 million, or $0.05 per share, basic and diluted, compared to $2.4 million, or $0.03 per share, basic and diluted, for the same period in 2025.
Total revenues increased by $32.0 million year to date to $75.6 million, from $43.6 million for the same period in 2025.¶2
Net income for the third quarter was $4.0 million, or $0.05 per share, basic and diluted, compared with $2.4 million, or $0.03 per share, a year earlier.¶1
Net income for the nine months ended September 30, 2026 was $26.1 million, or $0.33 per share, basic, and $0.31 per share, diluted.¶1
The company reaffirmed 2026 total revenue guidance of approximately $78.0 million to $83.0 million, including a $25.0 million milestone payment from Chiesi in Q1 2026.¶2¶3
Cash, cash equivalents, and short-term bank deposits were $48.5 million at September 30, 2026.¶4
- Total revenues, nine months 2026
- $75.6 million Nine months ended September 30, 2026, increased by $32.0 million year to date from $43.6 million for the same period in 2025¶2
- Net income, third quarter 2026
- $4.0 million Three months ended September 30, 2026, $0.05 per share, basic and diluted, compared to $2.4 million, or $0.03 per share, for the same period in 2025¶1
- Net income, nine months 2026
- $26.1 million Nine months ended September 30, 2026, $0.33 per share basic and $0.31 per share diluted, compared to a net loss of $1.1 million for the same period in 2025¶1
- 2026 total revenue guidance
- approximately $78.0 million to $83.0 million Reaffirmed; management expects to meet or exceed this range, including a $25.0 million Chiesi milestone received in Q1 2026¶3
- Cash, cash equivalents and short-term bank deposits
- $48.5 million As of September 30, 2026¶4
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $21.93M | $17.85M | $17.96M | $10.35M |
| Net Income | $3.96M | $2.36M | $3.24M | -$1.85M |
| EPS Diluted | $0.05 | $0.03 | $0.03 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR